Seres Therapeutics, Inc.

NASDAQ:MCRB

Biotechnology

Healthcare
$5.28 +1.70%

+$0.11 today

Market cap
$51.13M
Beta
0.11
P/E (TTM)
-1.3
EPS (TTM)
-$4.89
52W Low $5.31High $29.98

Volume 0.04M

Average 0.06M

MCRB Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Seres Therapeutics, Inc.NASDAQ: MCRB

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 49.3% from a year ago

Cash & equivalents stood at $29.83M at the end of Q1 FY2026, down 49.3% from a year earlier and down 34.8% from the prior quarter. Over 3 fiscal years it compounded at -34.5% a year.

Context

  • Cash & equivalents amounted to 25.4% of total assets at the end of Q1 FY2026, down 10.5 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -49.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$29.83M-34.8% QoQ
Last fiscal yearDec 2025
$45.77M+48.6% YoY
Year agoMar 2025
$58.85M-49.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.3%——
1 year+48.6%——
3-year CAGR-34.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
45.77M USD
Year-over-year change
+48.6%
4-year CAGR
-29.0%

Cash & Equivalents vs competitors

How MCRB compares with its peers on the latest reported figures

  • MCRB's Mar 2026 cash & equivalents of $29.83M is the 6th highest of the 9 companies compared; the peer median is $39.22M.
  • Its year-over-year change of -49.3% is the lowest of 9, against a peer median of +29.1%.
  • Cash & equivalents amounts to 25.4% of total assets for MCRB, versus a peer median of 69.5%.
MCRB Competitors Peer median
Cash & Equivalents for MCRB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IRDOpus Genetics, Inc.Mar 2026$59.96M +43.5%+1.9%89.8%
SPROSpero Therapeutics, Inc.Mar 2026$56.13M +14.8%-28.3%95.1%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$51.8M +71.7%-25.4%38.8%
SEERSeer, Inc.Mar 2026$47.32M -9.8%-3.9%17.4%
CGTXCognition Therapeutics, Inc.Mar 2026$31.13M +89.5%-4.0%86.1%
MCRBSeres Therapeutics, Inc.Mar 2026$29.83M -49.3%-34.5%25.4%
INOInovio Pharmaceuticals, Inc.Mar 2026$26.27M -34.2%-1.5%52.8%
ACTUActuate Therapeutics IncMar 2026$8.13M +109.1%-13.7%91.3%
HURATuHURA Biosciences, Inc.Mar 2026$6.3M +1.3%-36.7%21.2%
Peer median (excluding MCRB) $39.22M+29.1%-8.8%69.5%

Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents180M163.03M127.97M30.79M45.77M
Short-term Investments110.7M18.31M000
Net Receivables0004.75M360K
Inventory0029.65M00
Other Current Assets013.42M17.8M3.13M3.25M
Total Current Assets303.63M194.76M175.41M38.67M49.38M
Property, Plant & Equipment (Net)36.15M133.97M108.03M92.44M80.12M
Goodwill00000
Intangible Assets00000
Long-term Investments495K9.59M9.59M8.67M8.67M
Tax Assets00000
Other Non-current Assets14.59M10.47M65.57M31K31K
Total Non-current Assets51.23M154.02M183.19M101.14M88.82M
Total Assets354.86M348.78M358.6M139.81M138.19M
Account Payables13.74M17.44M3.64M4.08M1.68M
Short-term Debt0456K0010.39M
Tax Payables00000
Deferred Revenue16.82M4.26M7.73M00
Other Current Liabilities21.1M34.77M59.19M17.75M4.57M
Total Current Liabilities82.26M85.6M98.66M41.22M19.32M
Long-term Debt24.64M50.59M101.54M00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)87M92.43M95.36M00
Other Non-current Liabilities11.5M1.44M16.24M1.84M2.08M
Total Non-current Liabilities141.09M252.41M304.8M84.8M74.65M
Total Liabilities223.35M338M403.46M126.03M93.98M
Common Stock92K125K135K173K10K
Retained Earnings(614.35M)(864.51M)(978.24M)(978.1M)(972.4M)
Accumulated OCI(60K)(12K)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity131.51M10.78M(44.86M)13.78M44.22M
Total Debt49.21M162.59M198.78M91.64M82.97M
Net Debt(130.79M)(440K)70.82M60.85M37.2M

Seres Therapeutics, Inc.

NASDAQ:MCRB

Intrinsic Alpha fair value

Locked

Current Price

$5.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.